Development and Validation of a Prognostic Nomogram for Extremity Soft Tissue Leiomyosarcoma
Conclusions: The proposed nomogram is a reliable and robust tool for accurate prognostic prediction in patients with extremity soft tissue LMS. Introduction Soft tissue leiomyosarcoma (LMS) is an aggressive sarcoma, which originates from smooth muscle cells (1). Soft tissue LMS accounts for about 5–10% of all soft tissue sarcomas (2). It occurs in different sites, including the retroperitoneum, intraabdominal sites, and extremities (3). Extremity LMS comprised about 10–15% of extremity sarcomas, with a preference for the lower limb (4–6). Extremity LMS tends to have a better prognosis than uterine, retroperitoneal, or major vessel LMS (1, 7), but worse overall survival (OS) than other soft tissue sarcoma subtypes (8). Moreover, patients with metastasis usually have a poorer prognosis (2, 9, 10). Current treatment for extremity LMS includes systemic chemotherapy along with surgery and/or radiation therapy for local control. Surgical resection is the most widely accepted treatment modality (11). Significant independent predictors for survival in LMS patients are primary site, age, tumor location, tumor size, margin status, and histological grade (2, 12–14), whereas abdominal site, tumor size>15 cm, positive resection margin and higher histological grade predict poor survival. Further, tumor size and margin status were independent predictors of local recurrence, while tumor size and grade were independent predictors for metastasis in LMS patien...
Conclusions: The bibliometric analysis allowed to objectively record the productivity and visibility of the Regional System for Vaccines for Streptococcus pneumoniae in the Region. PMID: 32774349 [PubMed]
In this study, we found only minor ethnic differences in persistent pain. Similar living conditions and cultural features may explain these findings. PMID: 32780007 [PubMed - in process]
Publication date: Available online 11 August 2020Source: Journal of Oral BiosciencesAuthor(s): Sho Akashi, Takashi Nishida, Tomomi Mizukawa, Kazumi Kawata, Masaharu Takigawa, Seiji Iida, Satoshi Kubota
Publication date: Available online 11 August 2020Source: Carbohydrate PolymersAuthor(s): Sevil Vaghefi Moghaddam, Fatemeh Abedi, Effat Alizadeh, Behzad Baradaran, Nasim Annabi, Abolfazl Akbarzadeh, Soodabeh Davaran
Publication date: Available online 11 August 2020Source: Carbohydrate PolymersAuthor(s): Jingwen Luo, Tao Gong, Lixin Ma
Publication date: September 2020Source: Biomedical Signal Processing and Control, Volume 62Author(s): Silvia Malavasi, Alessandro Bevilacqua, Giampaolo Gavelli, Domenico Barone
Publication date: September 2020Source: Biomedical Signal Processing and Control, Volume 62Author(s): Hong Chen, Xianpan Pan, Xuesong Lu, Qinlan Xie
Publication date: July 2020Source: Biomedical and Environmental Sciences, Volume 33, Issue 7Author(s): Fei Ran WEI, Li Lin XIONG, Wei LI, Xue Rong WANG, Xin HONG, Bao An CHEN
Publication date: July 2020Source: Biomedical and Environmental Sciences, Volume 33, Issue 7Author(s): Qing Ming SHU, Xin Guo CHEN, Hong Ying ZHANG, Li Hong HUANG, Yong Liang ZHANG, Qing ZHANG
NF-κB transcription factors, driven by the IRAK/IKK cascade, confer treatment resistance in pancreatic ductal adenocarcinoma (PDAC), a cancer characterized by near-universal KRAS mutation. Through reverse-phase protein array and RNA sequencing we discovered that IRAK4 also contributes substantially to MAPK activation in KRAS-mutant PDAC. IRAK4 ablation completely blocked RAS-induced transformation of human and murine cells. Mechanistically, expression of mutant KRAS stimulated an inflammatory, autocrine IL-1β signaling loop that activated IRAK4 and the MAPK pathway. Downstream of IRAK4, we uncovered TPL2 (also k...
More News: Academia | Bladder Cancer | Bone Cancers | Bronchial Tumour | Cancer | Cancer & Oncology | Cancer of the Uterus | Carcinoma | Chemotherapy | China Health | Chondrosarcoma | CT Scan | Databases & Libraries | Epidemiology | Ewing's Sarcoma | France Health | Gastroenterology | Gastrointestinal Stromal Tumor (GIST) | Gastrointestinal Stromal Tumour (GIST) | Grants | Hepatocellular Carcinoma | Leiomyosarcoma | Liposarcoma | Liver Cancer | Medical Ethics | Middle East Health | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy | Orthopaedics | Osteosarcoma | Pain | Pain Management | PET Scan | Radiation Therapy | Radiography | Rare Diseases | Reproduction Medicine | Rhabdomyosarcoma | Sarcomas | Saudi Arabia Health | Science | Soft Tissue Sarcoma | Statistics | Study | Thrombosis | Training | UAE Health | Universities & Medical Training